About the project

Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer's disease modifying drugs

We are aiming to:

  • establish a strong network of academic-industrial partners with cutting-edge, unique proprietary technologies and knowledge
  • achieve scientific advancement in understanding the pathways of tau in neurodegeneration
  • adopt a unique panel of techniques and considering important interaction partners of pathologic tau
  • foster novel tools for neurodegeneration diagnostics and therapy

Project coordinator: 

CEITEC MU (Czech Republic)

Project partners: 

• Institute of Neuroimmunology, Slovak Academy of Sciences (Slovakia)  Latvian Institute of Organic Synthesis (Latvia)

Royal College of Surgeons (Ireland)  University of Pittsburgh (USA)  National University of Cuyo (Argentina) • GENETON s.r.o. (Slovakia) 

• BioVendor - Laboratorní medicína (Czech Republic) • DATAMEDRIX GmbH (Austria)  • Sanata Dharma University (Indonesia)

Former project partners:

 Oregon State University (USA)  University Health Network (Canada)  AXON Neurosciences (Slovakia)

Project duration: 66 months (01.01.2020 - 30.06.2025)
Project call: H2020-MSCA-RISE-2019
Total budget: 1 058 000

​This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 873127 – InterTAU.

This website reflects only the author's view and the Research Executive Agency (REA) is not responsible for any use that may be made of the information it contains.